K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · SANOFI US SERVICES INC.
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-19 | SNY | SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | $50K | Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to pharmaceutical IP, supply chain, and tarif |
| 2026-04-18 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $40K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
| 2026-04-15 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing. |
| 2026-01-20 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing. |
| 2026-01-20 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $30K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
| 2026-01-18 | SNY | SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | $50K | Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act (S.2296/H.R.3838/P.L.119-60), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole ma |
| 2025-10-20 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $30K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
| 2025-10-19 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing. |
| 2025-10-18 | SNY | SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | $50K | Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21). Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838), insulin price cap, VICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. H.R.1, |
| 2025-07-20 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing. |
| 2025-07-20 | SNY | SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | $50K | General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to pharmaceutical IP, supply chain, and tariffs. H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions. Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), insulin price cap, VICP Program, and PBM reform; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescriptio |
| 2025-07-17 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $40K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
| 2025-04-21 | SNY | SANOFI US SERVICES INC. | CROSSROADS STRATEGIES, LLC | $50K | Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), insulin price cap, VICP Program, and PBM reform; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rig |
| 2025-04-21 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $30K | There is no current bill filed. Working on Issues related to health care and drug pricing. There is no current bill filed. Working on Issues related to health care and drug pricing. |
| 2025-04-17 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $40K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |
| 2025-03-14 | SNY | SANOFI US SERVICES INC. | CHECKMATE GOVERNMENT RELATIONS | $0 | Issues related to health care and drug pricing. Issues related to health care and drug pricing. |
| 2025-01-19 | SNY | SANOFI US SERVICES INC. | THORN RUN PARTNERS | $40K | Issues related to insulin pricing. Issues related to Medicare Part D. Issues regarding vaccines. Issues related to the orphan drug tax credit. |